Aug 18, 2021
Jnana closes $50M series B round, picks PKU as lead indication
BioWorld
© 2022 Jnana Therapeutics - All rights reserved.
BOSTON, Mass., April 26, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced the appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Pagán will be responsible for spearheading the company’s finance, operations and IT functions, including capital […]
– Phase 1 clinical study expected to begin late this year – – Cryo-EM structure reveals Jnana’s proprietary inhibitors, identified using its RAPID platform, bind the target in a cryptic allosteric site – Boston, Mass., February 23, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but […]
Fierce Biotech
Pharmaceutical Business Review
Scripps Research, April 2020
Chemical and Engineering News, October 2018
This links to an external website. Merus is not responsible for any third party content.